




RealRate

PHARMACEUTICAL 2014

Melinta Therapeutics INC NEW
Rank 100 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Melinta Therapeutics INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Melinta Therapeutics INC NEW compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Melinta Therapeutics INC NEW is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 38% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	98,537
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,862
Liabilities, Non-Current	12,538
Other Assets	333
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	5,633
Other Net Income	-2,115
Other Revenues	7,813
Property and Equipment	138
Research and Development	41,300
Selling, General and Administrative Expense	9,433

Output Variable	Value in 1000 USD
Assets	99,008
Liabilities	29,032
Expenses	50,733
Revenues	7,813
Stockholders Equity	69,975
Net Income	-45,035
Comprehensive Net Income	-45,035
BaseVar	94,350
ECR before LimitedLiability	168%
Economic Capital Ratio	280%